The field of cancer research is rapidly evolving, with a growing focus on the intersection of cancer immunology, gene editing, and epigenetics. This ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

‘Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

While some mutations in the BRCA2 gene clearly indicate risks for breast and prostate cancer, thousands of less-common ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Yoltech Therapeutics Co. Ltd. has advanced YOLT-204 into the clinic for the treatment of transfusion-dependent β-thalassemia (TDT). If successful, YOLT-204 may provide an off-the-shelf curative ...

Robert F. Kennedy Jr., Trump’s pick to be health secretary, is keeping his financial stake in major vaccine litigation ...

If corn was ever jealous of soybean's relationship with nitrogen-fixing bacteria, advancements in gene editing could one day even the playing field. A recent study shows that gene-edited bacteria can ...